Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FAAH | O00519 | 11/20 | 0.53 |
| ▸ | PDE4D | Q08499 | 2/20 | 0.46 |
| ▸ | CNR1 | P21554 | 1/20 | 0.46 |
| ▸ | ACHE | P22303 | 1/20 | 0.46 |
| ▸ | PDE4A | P27815 | 1/20 | 0.46 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.46 |
| ▸ | PDE4C | Q08493 | 1/20 | 0.46 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.46 |
| ▸ | FFAR1 | O14842 | 3/20 | 0.43 |
| ▸ | FFAR4 | Q5NUL3 | 5/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2680645 | 0.85 | FAAH (0.54) | FAAHPDE4DCNR1ACHEPDE4A | |
| SCHEMBL5529188 | 0.83 | FAAH (0.48) | FAAHPDE4DCNR1ACHEPDE4A | |
| SCHEMBL2682323 | 0.82 | FAAH (0.49) | FAAHPDE4DCNR1ACHEPDE4A | |
| SCHEMBL2680718 | 0.79 | FAAH (0.85) | FAAHPDE4DCNR1ACHEPDE4A | |
| SCHEMBL1724861 | 0.79 | FAAH (0.46) | FAAHFFAR1FFAR4 | |
| SCHEMBL2682562 | 0.79 | FAAH (0.46) | FAAHFFAR1FFAR4 | |
| SCHEMBL2681410 | 0.75 | FAAH (0.85) | FAAHPDE4DCNR1ACHEPDE4A | |
| SCHEMBL1728639 | 0.75 | FAAH (0.85) | FAAHPDE4DCNR1ACHEPDE4A | |
| SCHEMBL3803873 | 0.74 | FFAR4 (0.49) | FAAHPDE4DPDE4APDE4BPDE4C | |
| SCHEMBL3803876 | 0.74 | FFAR4 (0.49) | FAAHPDE4DPDE4APDE4BPDE4C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2403338-B1 | IMIDAZOLE DERIVATIVES USEFUL AS MODULATORS OF FAAH AND AS FAAH IMAGING AGENTS | MERCK SHARP & DOHME (US) | 2017-07-26 | — | — | EP | disclosed |
| US-20130030000-A1 | PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF PAIN AND OTHER INDICATIONS | MERCK SHARP & DOHME CORP. | 2013-01-31 | — | — | US | disclosed |
| US-20120115894-A1 | IMIDAZOLE DERIVATIVES USEFUL AS MODULATORS OF FAAH AND AS FAAH IMAGING AGENTS | MERCK SHARP & DOHME CORP. (US) | 2012-05-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120115894-A1 | IMIDAZOLE DERIVATIVES USEFUL AS MODULATORS OF FAAH AND AS FAAH IMAGING AGENTS | FAAH, FAAH2, INMT | FAAH 1/4885PDE4D 393/4885CNR1 17/4885 |
| US-20130030000-A1 | PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF PAIN AND OTHER INDICATIONS | FAAH, FAAH2, CNR2 | FAAH 1/4885PDE4D 463/4885CNR1 14/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.